机译:FDA批准摘要:Rucaparib用于治疗有害BRCA突变相关晚期卵巢癌的患者
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Devices &
Radiol Hlth Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Devices &
Radiol Hlth Silver Spring MD USA;
US FDA Ctr Devices &
Radiol Hlth Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
US FDA Ctr Drug Evaluat &
Res Silver Spring MD USA;
机译:FDA批准摘要:Rucaparib用于治疗有害BRCA突变相关晚期卵巢癌的患者
机译:FDA批准摘要:使用三行或更多行化学疗法治疗有害生殖系BRCA突变的晚期卵巢癌患者的Olaparib单药治疗
机译:FDA批准摘要:Olaparib单药治疗有害种系BRCA-突变的晚期卵巢癌治疗,用三种或更多种化疗进行治疗
机译:一种用于检测BRCA1 / BRCA2基因突变和卵巢癌风险评估的集成微流体平台
机译:从自我癌症中确定基因Krca1 / 2中的突变吗?
机译:FDA批准摘要:Rucaparib用于治疗有害BRCA突变的转移性阉割前列腺癌的患者
机译:FDA批准摘要:Olaparib单药治疗有害种系BRCA-突变的晚期卵巢癌治疗,用三种或更多种化疗进行治疗